Evidence Shows That Estrogen Blocker Treatment Does Not Increase the Risk of Coronary Heart Disease in Breast Cancer Patients

New evidence shows that extended estrogen suppression treatment using an aromatase inhibitors for hormone receptor-positive postmenopausal breast cancer is safe; it does not increase the risk of coronary artery calcification, a sign of active coronary atherosclerosis, as some prior studies had indicated. An articleopens in new tab/window in the Canadian Journal of Cardiologyopens in new tab/window, published by Elsevier, details the findings from a retrospective, cross-sectional observational study that investigated the association between the duration of aromatase inhibitor treatment and the severity of coronary artery calcification in postoperative breast cancer patients.

Coronary artery calcification is a significant predictor of adverse outcomes in the general population, which is believed to be associated with atherosclerosis, the condition that causes angina and heart attacks. Despite estrogen's beneficial role in cardiovascular health, its suppression is often necessary in patients with breast cancer. Hormonal therapy, particularly the use of aromatase inhibitors (which block the production of estrogen), is a standard treatment after breast cancer surgery for postmenopausal women. While these therapies are effective in reducing cancer recurrence, there is increasing concern about their potential cardiovascular side effects, including acceleration of coronary artery atherosclerosis.

Lead investigator Yu Hiasa, MD, Department of Cardiology, Pulmonology, Hypertension & Nephrology, Ehime University Graduate School of Medicine, Toon, Japan, explains, “Although there is an ongoing discussion on the optimal duration of aromatase inhibitor therapy (5 years or 10 years), our data suggest that longer aromatase inhibitor use (as often used to prevent or suppress late recurrences or spread of breast cancer) is safe, at least in regard to coronary artery calcification.”

The investigators conducted a single-center, retrospective, cross-sectional observational study among 357 postmenopausal breast cancer patients who initiated adjuvant endocrine therapy with aromatase inhibitors for breast cancer between August 2010 and October 2022 as outpatients. Coronary artery calcification was quantified using a visual ordinal scoring system, and patient characteristics were assessed based on the presence of coronary artery calcification. Independent risk factors for elevated coronary artery calcification scores were identified through a multivariable logistic regression model.

Co-investigator Akinori Higaki, MD, PhD, Department of Cardiology, Pulmonology, Hypertension & Nephrology, Ehime University Graduate School of Medicine, Toon, Japan, adds, "Our analysis of the postoperative breast cancer patient cohort revealed that the duration of treatment with aromatase inhibitors and the presence of osteoporosis were not associated with coronary artery calcification."

In patients diagnosed with coronary artery calcification prior to the study, its severity was not impacted by the treatment.

In addition to the well-known risk factors for coronary artery calcification such as older age, hypertension, and diabetes mellitus, researchers found that a lower hemoglobin level is also an independent risk factor for coronary artery calcification.

In an accompanying editorialopens in new tab/window, Ibrahim Alfaris, MBBS, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, notes, "Identifying low hemoglobin as a novel, highly significant risk factor for coronary artery calcification in this population raises the possibility of adding anemia as an indication for cardiovascular screening. Anemia is not typically noted in classic atherosclerotic cardiovascular disease risk calculators or expert recommendations, and this finding could lead to changes in screening practices for postmenopausal women undergoing aromatase inhibitors therapy."

Dr. Alfaris concludes, "Understanding the association between the duration of aromatase inhibitors treatment and the severity of coronary artery calcification in postoperative breast cancer patients is crucial, as it impacts the long-term health management of breast cancer survivors, who are at significant risk for cardiovascular disease due to the anti-estrogenic effects of their therapy."

Notes for editors

The article is “Impact of Aromatase Inhibitors Treatment Duration on Coronary Artery Calcification in Postoperative Patients with Breast Cancer,” by Yu Hiasa, MD, Akinori Higaki, MD, PhD, Yoshiaki Kamei, MD, PhD, Tomoaki Nishikawa, MD, Ryo Miyabe, MD, Tomoki Fujisawa, MD, Shigehiro Miyazaki, MD, Yusuke Akazawa, MD, Toru Miyoshi, MD, Hiroshi Kawakami, MD, PhD, Fumiyasu Seike, MD, PhD, Haruhiko Higashi, MD, PhD, Shunsuke Tamaki, MD, PhD, Kazuhisa Nishimura, MD, PhD, Katsuji Inoue, MD, PhD, Shuntaro Ikeda, MD, PhD, and Osamu Yamaguchi, MD, PhD (https://doi.org/10.1016/j.cjca.2024.05.012opens in new tab/window).

The article is openly available for 30 days at https://onlinecjc.ca/article/S0828-282X(24)00402-1/fulltextopens in new tab/window.

Journalists wishing to speak to the authors should contact Akinori Higaki, MD, PhD, at +81-89-960-5303 or [email protected]opens in new tab/window.

The editorial is "Aromatase Inhibitors and Coronary Artery Calcification in Breast Cancer Patients," by Ibrahim Alfaris, MBBS (https://doi.org/10.1016/j.cjca.2024.07.016opens in new tab/window).

The editorial is openly available for 30 days at https://onlinecjc.ca/article/S0828-282X(24)00569-5/fulltextopens in new tab/window.

Journalists wishing to speak to the author should contact Ibrahim Alfaris, MBBS, at [email protected]opens in new tab/window.

Both articles appear in the Canadian Journal of Cardiology, published by Elsevier.

Full text of the articles is also available to credentialed journalists upon request. Contact Astrid Engelen at +31 6 14395474or [email protected]opens in new tab/window for a copy of the PDFs or more information.

About the Canadian Journal of Cardiology

The Canadian Journal of Cardiologyopens in new tab/window (CJC) is an international, peer-reviewed journal that disseminates new knowledge in cardiology and cardiovascular science. It is the preferred Canadian cardiovascular medicine peer-reviewed publication and is an official journal of the Canadian Cardiovascular Societyopens in new tab/window (CCS). The CJC publishes original reports of clinical and basic research relevant to cardiovascular medicine, as well as practice guidelines, editorials, review articles, and case reports. www.onlinecjc.caopens in new tab/window

About the Editor-in-Chief

Editor-in-Chief Stanley Nattel, MD, is Paul-David Chair in Cardiovascular Electrophysiology and Professor of Medicine at the University of Montreal and Director of the Electrophysiology Research Program at the Montreal Heart Institute Research Center.

About the Canadian Cardiovascular Society (CCS)

The CCSopens in new tab/window is the national voice for cardiovascular clinicians and scientists, representing more than 2,300 cardiologists, cardiac surgeons and other heart health specialists across Canada. We advance heart health for all by setting standards for excellence in heart health and care, building the knowledge and expertise of the heart team, and influencing policy and advocating for the heart health of all Canadians. For further information on the CCS visit https://www.ccs.ca/enopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.